Thought Leadership

Latest Report

Obesity matters for drug developers

Close to 40% of the US adult population is now obese and the WHO and AMA define obesity as a disease. So it’s perhaps no surprise that Evaluate Pharma is forecasting sales by indication of $50bn in 2028 and CAGR between 2021 and 2028 at around 36%.  The R&D pipeline is filling up as more and more companies try to grab a slice of this…

Report library

Thumbnail

Medtech - Going steady

The medtech sector, like the wider pharma market, has been having a tough time. There are, however, glimmers of light and some interesting developments – including…

Thumbnail

Vantage Top 10 Most Read Report

The Evaluate Vantage team has rounded up our Top 10 Most-Read stories. Get up to speed on the big issues that have captured the interest and attention of your peers and…

Thumbnail

Asco 2022 eBook

Thousands of abstracts were submitted for the recent Asco meeting in Chicago and 40,000 oncology professionals gathered to delve into cutting-edge research,…

Thumbnail

Q1 2022: Choppy Waters eBook

If the first quarter of 2022 was a bellwether for the rest of year, many in the drug development market might want to don wet weather gear and hunker down for a blustery…

Thumbnail

Orphan Drug 2022 Report

Treatments for orphan indications and rare diseases are no longer a niche area of focus for developers. Orphan products have become one of the fastest growing areas of…